双鹭药业
(002038)
| 流通市值：70.25亿 | | | 总市值：84.76亿 |
| 流通股本：8.51亿 | | | 总股本：10.27亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 643,139,595.37 | 683,831,097.67 | 735,397,510.2 | 704,901,879.94 |
| 应收票据及应收账款 | 197,439,901.29 | 200,470,744.96 | 188,151,075.84 | 198,763,001.1 |
| 应收账款 | 197,439,901.29 | 200,470,744.96 | 188,151,075.84 | 198,763,001.1 |
| 应收款项融资 | 1,799,649.6 | 98,648.4 | 3,623,908.09 | 8,016,366.81 |
| 预付款项 | 221,541,714.22 | 121,023,441.52 | 114,998,065.6 | 121,141,856.38 |
| 其他应收款合计 | 29,875,056.03 | 35,251,823.85 | 17,067,447.38 | 17,502,600.84 |
| 应收股利 | - | 14,700,000.01 | - | - |
| 存货 | 171,098,630.81 | 144,456,874.27 | 149,611,885.77 | 159,878,991.55 |
| 一年内到期的非流动资产 | 55,234,375 | 54,765,625.02 | - | - |
| 其他流动资产 | 790,682,490.51 | 791,520,862.94 | 702,777,831.03 | 689,463,907.72 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 2,675,312,708.26 | 2,639,981,026.24 | 2,048,072,703.91 | 2,039,044,474.34 |
| 非流动资产: | | | | |
| 长期股权投资 | 911,366,506.82 | 905,919,506.61 | 899,759,771.71 | 902,609,619.54 |
| 其他非流动金融资产 | 276,425,824.7 | 276,414,861.26 | 629,219,312.05 | 656,573,547.8 |
| 投资性房地产 | 13,855,701.39 | 14,082,133.14 | 14,308,564.89 | 14,534,996.64 |
| 固定资产 | 437,013,954.67 | 446,361,091.84 | 439,138,997.51 | 449,875,930.8 |
| 在建工程 | 60,189,386.97 | 56,974,742.72 | 60,095,920.31 | 60,060,040.31 |
| 无形资产 | 657,542,270.43 | 693,772,760.63 | 643,070,324.17 | 587,721,715.89 |
| 开发支出 | 477,609,874.64 | 449,896,301.73 | 434,237,048.1 | 481,450,717.45 |
| 长期待摊费用 | 1,997,641.06 | 1,997,641.06 | 2,191,111.14 | 2,191,111.14 |
| 递延所得税资产 | - | - | 39,751,901.21 | 37,942,608.94 |
| 其他非流动资产 | 800,646,130.83 | 792,361,780.21 | 857,764,713.99 | 854,822,572.31 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 3,636,647,291.51 | 3,637,780,819.2 | 4,019,537,665.08 | 4,047,782,860.82 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 6,311,959,999.77 | 6,277,761,845.44 | 6,067,610,368.99 | 6,086,827,335.16 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 258,497,412.51 | 250,755,038.49 | 168,241,803.39 | 176,290,106.03 |
| 其中：应付票据 | 37,593,280 | 37,593,280 | - | - |
| 应付账款 | 220,904,132.51 | 213,161,758.49 | 168,241,803.39 | 176,290,106.03 |
| 预收款项 | 1,360,701.82 | 485,450 | 1,827,538.68 | 611,700 |
| 合同负债 | 9,701,484.78 | 14,807,217.19 | 11,138,500.75 | 15,287,389.72 |
| 应付职工薪酬 | 34,710,210.91 | 38,919,326.35 | 27,882,088.51 | 26,570,958.56 |
| 应交税费 | 845,057.63 | 8,153,866.22 | 3,445,694.8 | 7,190,216.49 |
| 其他应付款合计 | 43,051,325.42 | 59,192,263.59 | 48,006,589.25 | 50,110,353.7 |
| 其他流动负债 | 745,748.03 | 1,013,110.45 | 472,952.34 | 634,934.36 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 348,911,941.1 | 373,326,272.29 | 261,015,167.72 | 276,695,658.86 |
| 非流动负债: | | | | |
| 递延收益 | 44,165,123.1 | 47,041,076.17 | 47,210,076.17 | 47,210,076.17 |
| 递延所得税负债 | 39,169,626.72 | 47,356,994.62 | 66,654,246.12 | 70,239,059.02 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 83,334,749.82 | 94,398,070.79 | 113,864,322.29 | 117,449,135.19 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 432,246,690.92 | 467,724,343.08 | 374,879,490.01 | 394,144,794.05 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,027,350,000 | 1,027,350,000 | 1,027,350,000 | 1,027,350,000 |
| 资本公积 | 49,615,655.87 | 49,615,655.87 | 43,846,655.86 | 43,846,655.86 |
| 其他综合收益 | 13,474,826.25 | 13,474,826.25 | 666,996.65 | 666,996.65 |
| 盈余公积 | 632,410,430.74 | 632,410,430.74 | 632,410,430.74 | 632,410,430.74 |
| 未分配利润 | 4,147,899,805.36 | 4,077,765,187.3 | 3,978,641,325.31 | 3,978,237,370.68 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 5,870,750,718.22 | 5,800,616,100.16 | 5,682,915,408.56 | 5,682,511,453.93 |
| 少数股东权益 | 8,962,590.63 | 9,421,402.2 | 9,815,470.42 | 10,171,087.18 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 5,879,713,308.85 | 5,810,037,502.36 | 5,692,730,878.98 | 5,692,682,541.11 |
| 负债和股东权益合计 | 6,311,959,999.77 | 6,277,761,845.44 | 6,067,610,368.99 | 6,086,827,335.16 |
| 公告日期 | 2024-04-24 | 2024-04-24 | 2023-10-26 | 2023-08-25 |
| 审计意见(境内) | | 标准无保留意见 | | |